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ABSTRACT
Objective: The objective of this study was to assess the
impact of medication treatment on Medicaid costs for
persons with schizophrenia.
Methods: Michigan Medicaid claims from January 1995
through September 1998 were analyzed for persons
with schizophrenia diagnoses who initiated olanzapine
(n = 458), risperidone (n = 481), or haloperidol (n = 252)
treatment between January 1996 and September 1997.
Total and component Medicaid payments were compared
for the year after treatment initiation, with simultaneous
adjustment for patient demographics, comorbid condi-
tions, prior medication use, prior service use, and prior
year costs.
Results: Signiﬁcant baseline differences existed between
the groups in prior medication and service use. Adherence
to index medication varied between the groups
(O = 60%; R = 54%; H = 37%; P < = .01 for each pair-
wise comparison). Average postperiod costs were $14,512
per subject. After baseline adjustment, there were no sig-
niﬁcant differences in mean total cost. Excluding index
medication costs, the olanzapine group’s average cost was
signiﬁcantly lower than risperidone (–$1,791, P = .002)
and haloperidol (–$2,080, P = .003), whereas the risperi-
done and haloperidol groups were not signiﬁcantly differ-
ent. The differences were driven by signiﬁcantly lower
cost for inpatient services for other medications among
the olanzapine group.
Conclusion: Total costs of schizophrenia care associated
with olanzapine, risperidone, or haloperidol were similar,
but component costs differed. Relative to risperidone
or haloperidol, olanzapine may have a higher acquisition
cost, but may decrease inpatient costs and be associated
with more optimal medication use patterns. Use of risp-
eridone may also increase pharmacy costs and be associ-
ated with greater persistence, relative to haloperidol.
Keywords: olanzapine, risperidone, haloperidol, Medic-
aid, schizophrenia, cost of care.
Introduction
Ten years ago, most people in the United States with
schizophrenia were receiving antipsychotic medica-
tions that had been developed in the 1940s and
1950s. One of the most commonly used med-
ications was haloperidol. Today, schizophrenia
pharmacotherapy is dominated by two newer med-
ications: risperidone, ﬁrst available in February
1994, and olanzapine, introduced in October 1996.
Each of these newer medications has demonstrated
clinical advantages over haloperidol, but each also
has a cost per day that is many times greater than
haloperidol.
The issue of clinical beneﬁt versus price is
increasingly critical in the treatment of severe men-
tal illness. With the current economic recession,
state governments are facing very large budget
shortfalls [1], and Medicaid represents about 15%
of each state’s general fund budget. The recession
also increases the number of people eligible for
Medicaid beneﬁts [2,3]. Medicaid administrators
are facing great pressures to limit spending while
continuing to deliver quality health care to a grow-
ing population. Administrators face an added prob-
lem of losing about $1.33 in federal Medicaid
matching funds for every $1.00 of state funding
they cut [4]. In the center of all this are the state
mental health service systems, which depend very
heavily on Medicaid funding. Most care for schiz-
ophrenia is delivered through these systems [5].
Within schizophrenia treatment, the rapid
increase in use of the newer medications and a
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decrease in use of psychiatric hospitalizations [5]
have combined to produce a disproportionate
increase in the pharmacy budget. As a result, there
is increased examination of the value provided by
the more expensive medications. Randomized stud-
ies indicate that both olanzapine and risperidone
have greater efﬁcacy than haloperidol in a variety of
symptoms [6–9], are associated with fewer extrapy-
ramidal symptoms [10], and have greater main-
tenance of response or less relapse [11,12].
Nevertheless, olanzapine and risperidone are not
interchangeable. Each has a unique pharmacologic
proﬁle [13] and consequently a distinct safety and
efﬁcacy proﬁle. Randomized studies comparing
olanzapine and risperidone in schizophrenia treat-
ment have had mixed results regarding their relative
efﬁcacy [14–16]. Risperidone’s safety proﬁle has
resulted in recommendations that risperidone doses
be kept below 6 mg per day [17–19], whereas olan-
zapine has been associated with more weight gain
than risperidone [20]. The one randomized com-
parison of olanzapine (n = 172) and risperidone
(n = 167) that evaluated maintenance of response
found an advantage for olanzapine (88% vs. 68%
maintained response until week 28, Kaplan–Meyer
P = .001) [14].
Relatively few well-designed studies have been
conducted on the impact of these medications on
the costs of care. Hamilton et al. [21] published the
only randomized total cost comparison of olanzap-
ine (n = 551) and haloperidol (n = 266). The Ham-
ilton study was divided into two phases: acute
treatment (the ﬁrst 6 weeks) and maintenance treat-
ment (weeks 7 through 52). Total costs associated
with olanzapine were signiﬁcantly lower in the
acute phase (–$388, P = .03), but not in the main-
tenance phase (–$636, P = .13). In both phases, sig-
niﬁcantly higher medication costs associated with
olanzapine were more than offset by signiﬁcantly
lower inpatient and outpatient costs [21]. Likewise,
the only randomized cost comparison of olanzapine
and risperidone found that, over 28 weeks of treat-
ment, olanzapine was associated with higher medi-
cation costs (+$793, P = .001), but lower inpatient
costs (–$3644, P = .09), resulting in no signiﬁcant
difference between olanzapine and risperidone in
total costs (–$2417, P = .21) [22]. Analyses of cost
from randomized comparisons of risperidone and
haloperidol have not been published. The results
of these two randomized studies are somewhat
dependent on assumptions made about missing
data; as happens in most prospective studies, a
notable portion of each study’s subjects did not
complete the full study [9–14].
Most naturalistic (i.e., nonrandomized) studies
of total health-care costs associated with these med-
ications include very little adjustment for baseline
differences between treatment groups. This lack of
adequate adjustment casts some doubt on the valid-
ity of their results, because baseline assessments of
olanzapine and risperidone initiators frequently
reveal differences in prior costs or service use [23–
28] and in prior medication use [24,26–31]. Among
those nonrandomized schizophrenia total cost stud-
ies making some adjustment for subjects’ prior
service use, olanzapine has been associated with
adjusted total costs that were statistically similar to
those of risperidone (+$566 over 6 months, P = .3)
[27] or lower than those of risperidone (–$693
over 1 year [24], P = .03; –$1834 over 1 year [32],
P < .05). In the one study that presented adjusted
component costs, the olanzapine group’s medica-
tion costs were signiﬁcantly higher than the risperi-
done group’s (+$1145, P < .0001). Nevertheless,
this difference was more than offset by signiﬁcantly
lower medical service costs (–$2,979, P < .002)
[32]. A fourth nonrandomized comparison within
schizophrenia, using less extensive adjustment,
found olanzapine to be associated with a signiﬁcant
increase in total cost relative to risperidone (+$5752
over 1 year, P = .009), with medication cost com-
prising only a small part of that difference (+$870,
P < .001) and the greater part of the difference
being attributable to hospitalizations (+$5434,
P < .02) [33].
Two naturalistic studies have compared total
costs of haloperidol and risperidone in the treat-
ment of schizophrenia, adjusting for prior service
use. Adjusted total costs associated with risperidone
were statistically similar to those of haloperidol
(+$370/month, P = .09) [34] or lower (–$365/
month, P = .005) [35]. Both studies showed
adjusted component costs, both ﬁnding greater
medication cost associated with risperidone (+$101/
month [34], P < .001; +$175/month [35], P < .001)
and one ﬁnding this to be more than offset by lower
inpatient costs (–$425/month, P = .0003) [35].
A common result across all these studies is that
the more expensive medication was never associ-
ated with higher total costs. In fact, the relative
increase in medication costs was often counterbal-
anced by an even greater decrease in inpatient costs.
This may reﬂect some clinical advantage, even in the
absence of dramatic cost savings [36].
Millman USA, the actuarial ﬁrm for the State of
Michigan, Department of Community Health; and
Eli Lilly and Company, the manufacturer of olan-
zapine, conducted this study in response to the
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Michigan Medicaid health management organiza-
tion’s concerns regarding pharmaceutical treatment
costs for persons with schizophrenia. The objective
was to determine whether olanzapine or risperidone
was associated with reductions in other health-care
expenditures, relative to haloperidol. Haloperidol
was also included, as a reference point, so that the
olanzapine and risperidone comparison might be
interpreted within a broader context. Among stud-
ies comparing costs associated with olanzapine and
risperidone, this study is unique in combining a
large number of subjects, comprehensive adjust-
ment for baseline differences, analysis of both total
costs and the component costs, and inclusion of
a ﬁrst-generation antipsychotic medication as a
benchmark. It contributes one more reference point
to improve understanding of how both patients and
health systems are affected by these common schiz-
ophrenia treatments. Unique aspects of this study
include several sensitivity analyses to clarify the
generalizability of the results, estimates of medica-
tion impacts on heath-care component costs made
with extensive adjustments for potential confound-
ers, and the use of a relatively novel approach for
multivariate analysis of skewed cost data.
Methods
Data
The data were drawn from the Michigan Medicaid
administrative claims data set, used by the actuaries
for the ﬁnancial analyses for Michigan’s Depart-
ment of Community Health (MDCH). Duplicate
claims, adjustments, and other inconsistencies were
resolved in coordination with MDCH.
Population
Inclusion and exclusion criteria were deﬁned a pri-
ori. Using the Michigan Medicaid eligibility ﬁle and
administrative claim records, we selected persons
receiving at least 1 inpatient or 2 outpatient diag-
noses of schizophrenia [37] within 12 months
before initiating therapy with the oral forms of
olanzapine, risperidone, or haloperidol. Data from
January 1995 through September 1998 were avail-
able. To allow for analysis of a 1-year prior period
and a 1-year postperiod, the therapy initiations
included were those between January 1, 1996, and
September 30, 1997. Olanzapine was ﬁrst marketed
halfway through this period, in October 1996. The
period prior to olanzapine’s availability was
included to provide sufﬁcient numbers of rispe-
ridone and haloperidol initiators. A sensitivity
analysis was also performed to assess whether com-
paring only those persons initiating an index medi-
cation after October 1996 had a notable effect on
the primary analysis results.
Therapy initiation with the index medication
(olanzapine, risperidone, or haloperidol) was de-
ﬁned as the ﬁrst prescription ﬁll date after at least
6 months without a ﬁll date for that medication. To
have clearly distinguished study groups, persons
using more than one study medication in the ﬁrst
30 days on or after that ﬁrst ﬁll date were excluded,
although subjects were permitted to use a nonstudy
antipsychotic during that period. We required con-
tinuous Medicaid enrollment for at least 1 year
before and 1 year after initiation of the index med-
ication, so that subjects might be adequately
characterized at study baseline and at follow-up.
Persons were excluded if they had extensive use of
inpatient services—that is, if they had been hospi-
talized for more than 60 of the 90 days before
initiation of the index medication, because data
on medication use during inpatient stays were
not available and because the service use of these
recently institutionalized persons was likely to be
qualitatively distinct from the rest of the popula-
tion. Schizophrenia was deﬁned by a diagnosis code
of 295 per the International Classiﬁcation of Dis-
eases, 9th revision [38].
Many Medicaid clients with schizophrenia qual-
ify for Medicare beneﬁts through their disability
level and work history. Medicare becomes the ﬁrst
payer for health services for these dually enrolled
persons and reimburses the majority of costs for
physician services and hospitalizations. But Medi-
care does not pay for prescription drugs or Com-
munity Mental Health Board (CMHB) services. As
a direct result, prescription drugs and CMHB serv-
ices comprise a greater portion of the Medicaid
expenditures for dually enrolled clients than for
Medicaid-only clients. Because of this difference in
payment systems, it was not reasonable to combine
dually enrolled clients with Medicaid-only clients in
a single cost analysis. The complete analysis of the
Medicaid-only population is presented in this article
because of the more complete capture of their total
costs within Medicaid administrative claims data.
Nevertheless, because dually enrolled clients make
up a large portion of the Medicaid population with
schizophrenia, the results from a parallel analysis of
that population are also brieﬂy discussed.
There were 3642 study medication initiations for
schizophrenia treatment between January 1, 1996,
and September 30, 1997, for persons continuously
enrolled in Medicaid for the 1 year before and after
the medication initiation date. Of these, 429 were
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excluded for receiving more than one study drug
within 30 days after the treatment initiation date.
The primary analysis excludes 871 olanzapine, 701
risperidone, and 350 haloperidol subjects, owing to
dual Medicaid and Medicare enrollment. Another
14 olanzapine, 21 risperidone, and 10 haloperidol
subjects were excluded for having been hospitalized
for more than 60 of the 90 days before initiation
of the index medication. This excluded group had
average annual costs of over $100,000 per year in
both the prior and the postperiods. Finally, 11 olan-
zapine, 25 risperidone, and 19 haloperidol subjects
were excluded as cost outliers, total costs exceeding
$55,000 in the prior period or the postperiod,
although an outlier sensitivity analysis was also per-
formed including these subjects. This study includes
the remaining 458 olanzapine, 481 risperidone, and
252 haloperidol subjects.
Each initiation of an index medication that met
the inclusion criteria was treated as an independent
subject in the analysis, even if the treated person
had already contributed another qualifying treat-
ment initiation. For example, if a person initiated
treatment with risperidone on March 1, 1996, and
then initiated treatment with haloperidol on June 1,
1997, the person would contribute two “subject”
records to the analysis, one for risperidone with an
index date of March 1, 1996, and the other for
haloperidol with an index date of May 1, 1997.
Twenty-eight persons contributed two qualifying
index medication initiations to the ﬁnal sample,
with the second always occurring at least 1 year
after the ﬁrst.
Measures
Persistence and concomitant antipsychotic use were
measured to characterize index medication utiliza-
tion patterns. Three index medication persistence
measures were calculated for each study group:
1) the percentage of subjects whose prescription
records indicated possession of the index medica-
tion 3 months (93 days) after initiating treatment;
2) the mean number of days to ﬁrst gap in therapy;
and 3) the mean number of days with the index
medication, as a percentage of the 365-day postpe-
riod. In the ﬁrst measure, the 93rd rather than 90th
day was used to increase likelihood that the subjects
not only ﬁlled three 30-day prescriptions, but also
actually used up those prescriptions and ﬁlled
another. A gap in therapy was deﬁned as over
2 weeks between expending a prescription day’s
supply and ﬁlling the next prescription. Number of
days with medication was deﬁned as the postperiod
days covered by the day’s supply of any prescription
for the index medication. Concomitant antipsy-
chotic use was measured as the percentage of sub-
jects in each group using antipsychotic medications
other than olanzapine, risperidone, or haloperidol
on the index date and 3 months later. To compare
these various measures, chi-square tests were used
for 1), univariate proportional hazards regression
for 2), and t tests for 3) (in days).
The explanatory variables for the cost analyses
were developed a priori and included demograph-
ics, comorbid conditions, prior medication use,
prior services use, and prior costs. Medicaid pro-
gram was included, because the Blind and Disabled
Program requires that clients meet disability criteria
not present in the other income- and age-based
Medicaid programs. Index medication initiation
date, by calendar quarter, was included as an adjust-
ment for temporal trends in cost or service use. To
control for variation in subjects’ tendency to use
high cost mental health services, variables repre-
senting prior utilization of inpatient services with a
schizophrenia diagnosis and utilization of speciﬁc
CMHB and hospital services were used. Likewise,
to adjust for subjects’ baseline value of the outcome
(i.e., cost), variables were calculated representing
each of four health-care component costs in the
prior period. Age was coded in years, with both age
and age-squared terms being entered into the anal-
yses. Comorbidity variables, prior medication use,
and prior service use were based on the 12 months
before initiation of the index medication. Popula-
tion health-care costs are greatly inﬂuenced by prev-
alent comorbidities requiring frequent service use,
so three comorbid condition variables were created,
based on receipt of medications speciﬁc to diabetes,
cardiovascular illness, or asthma. Use of antimanic
medications was used as a proxy for comorbid
mania. Variables were included for prior clozapine
use as an indicator of treatment refractory subjects,
prior depot use as an indicator of lack of medication
adherence, number of prior antipsychotic medica-
tions as an indicator of treatment refractoriness or
complexity, and having an antipsychotic other than
the three study medications in use when the subject
initiated the index medication, to indicate whether
the subject might be switching medications rather
than starting a new treatment episode [24,27,39–
41]. Speciﬁc CMHB service variables included
assertive community treatment (ACT), case man-
agement services, day program services, and resi-
dential services. Schizophrenia-related hospital use
was deﬁned as a hospitalization with a discharge
diagnosis of schizophrenia. Costs encompassed all
claims paid by Medicaid for services in the 365 days
Gibson et al.26
preceding initiation of the index treatment (the
prior period). Total prior payments were divided
into four components: inpatient, physician, CMHB,
and outpatient medication. Inpatient costs represent
hospital or long-term care facility services. Physi-
cian costs primarily represent ofﬁce visits and
consultations. CMHB costs primarily represent day
programs, ACT, case management, and residen-
tial support services. Outpatient medication costs
include all medication costs other than those
incurred in an inpatient setting. Inpatient medica-
tion payments were contained within inpatient
facility payments and could not be analyzed
separately.
All explanatory variables were binary, with the
exception of age, index medication initiation quar-
ter, inpatient days, and prior costs. Baseline differ-
ences between each pair of study groups were
compared using chi-square tests for binary varia-
bles, and t test for continuous variables (Table 1).
The primary dependent variable was the total
amount paid by Michigan Medicaid for each sub-
ject’s health care in the 365 days starting at treat-
ment initiation (the postperiod). To evaluate the
effect of each index medication independent of its
cost, total costs minus the subject’s index medica-
tion costs were also assessed. Finally, to better
understand what services were most responsible for
changes in total cost, total payments were divided
into cost components, as described in the prior
period measures: inpatient, physician, CMHB, and
outpatient medication. The outpatient medication
component was divided into index medication costs
and costs for other medications.
Analysis
An intent-to-treat analysis was used, comparing
olanzapine, risperidone, and haloperidol initiators’
costs in the postperiod, after adjusting for prior
period costs and the other baseline characteristics.
Least squares linear regression models were used.
Index medication was indicated with dummy vari-
ables, one for risperidone and one for haloperidol,
with olanzapine being the reference group. The
other explanatory variables were identiﬁed a priori
and are described above. Separate regressions were
performed for each dependent variable: total pay-
ment in the postperiod, total costs minus the
subject’s index medication payments, inpatient pay-
ments, physician payments, CMHB payments,
index medication payments, and other medication
payments. All explanatory variables were included
Table 1 Subjects’ characteristics at initiation of  their index medication
Medication Haloperidol Risperidone Olanzapine P value*
Number
Mean age, years (SD)
252
39.7 (10.2)
481
40.5 (11.8)
458
40.7 (10.8)
.786
Women (%) 53 48 53 .108
Medicaid Program:
Blind and Disabled (%)
95 95 98 .031
Using another antipsychotic
on index date (%)
19 39† 59† <.001
Medication use in prior 12 months (%)
Clozapine 7 7 17† <.001
Depot 23 13† 20 .002
Other antipsychotic 33 31 38 .028
Antimanic agent
(lithium or anticonvulsant)
33 28 34 .028
Asthma medications 17 21 21 .858
Cardiovascular medications 25 27 23 .149
Diabetes medications 6 7 6 .320
Service use in prior 12 months (%)
Residential services 2 4 5 .345
Assertive community treatment 17 20 29† <.001
Day program services 8 8 10 .354
Case management services 48 51 56 .098
Mean number (SD) of
diagnosis-related inpatient days
16.3 (21.7) 10.4 (18.1)† 6.1 (12.8)† <.001
Any diagnosis-related
inpatient days (%)
62 45† 31† <.001
Service cost (SD) in prior 12 months
Inpatient costs $8,428 ($10,102) $6,080 ($8,851)† $3,925 ($7,029)† <.001
Physician costs $1,071 ($1,207) $1,111 ($1,451) $836  ($1,340)† .003
CMHB costs $3,735 ($4,878) $3,874 ($4,787) $5,900 ($5,857)† <.001
Medication costs $1,463 ($1,987) $1,311 ($1,685) $2,371 ($2,347)† <.001
*P values are based on chi-square or t test statistics comparing the risperidone and olanzapine groups.
†P value < .05 versus haloperidol.
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in each model, to assure thorough adjustment for
potential confounding, and to allow for direct com-
parisons of medication effects across the models.
Least squares linear regression produces statisti-
cally unbiased estimates of the mean effects of the
independent variables, no matter what the error dis-
tribution, assuming that the independent variable
values are ﬁxed, having no measurement error,
and that all inﬂuential independent variables are
included and appropriately speciﬁed [42]. Never-
theless, the estimates of statistical signiﬁcance of
those coefﬁcients can be misleading, if the error
is not normally distributed or is heteroscedastic.
Unfortunately, health-care cost distributions are
almost always very skewed (non-normal), with var-
iance increasing as a function of costs (hetero-
scedastic) [43]. In this analysis, least squares
regression was used to produce estimates of medi-
cation and other independent variable effects. The
statistical signiﬁcance indications in Table 3 are
based on the usual t tests of coefﬁcients over their
standard deviations. However, to assure reliable P
values for the effects of greatest interest, randomi-
zation tests using 100,000 iterations of each model
were also performed. Randomization tests are valid
even in the presence of skewed and heteroscedastic
distributions, so the P values from these randomi-
zation tests were considered to be the most reliable
measure of statistical signiﬁcance [44]. For each
dependent variable, each pairwise medication
comparison was assessed: olanzapine versus ris-
peridone, risperidone versus haloperidol, and
haloperidol versus olanzapine.
The randomization tests were performed as fol-
lows: To compare the effect of olanzapine versus
risperidone on total cost 1) the combined group of
olanzapine and risperidone subjects was randomly
divided into two groups of 458 and 481 subjects,
mimicking the olanzapine and risperidone group
sizes. 2) The regression model was run again, with a
new variable indicating the randomly assigned
group status, rather than the variable indicating
olanzapine versus risperidone status. 3) These two
steps were repeated 100,000 times, with each result-
ing coefﬁcient for the randomly assigned group sta-
tus variable being saved as a data point in the null
hypothesis distribution. This null hypothesis distri-
bution represented the expected distribution of the
olanzapine versus risperidone coefﬁcient if the dif-
ference between the medications were only due to
random variation. 4) The actual coefﬁcient con-
trasting olanzapine versus risperidone was placed
within the distribution of the null hypothesis coef-
ﬁcients. 5) Two-tailed P values were calculated as
the percentage of null hypothesis distribution data
points that were more extreme than the actual coef-
ﬁcient, plus the percentage that were more extreme
than its negative value [44].
To improve the ﬁt of the models, subjects with
total costs above the 95th percentile were excluded
(total costs exceeding $55,000 in the prior period or
the postperiod). A separate regression analysis was
run without this exclusion, to evaluate whether this
exclusion had a notable effect on the results. The
results are presented under “Sensitivity Analysis.” A
ﬁnal sensitivity analysis was performed to assess
whether notable differences in monotherapy at ini-
tiation of the study medication greatly inﬂuenced
the results. A statistical signiﬁcance threshold of .05
was used throughout the analysis.
Results
Baseline Characteristics
The subjects’ characteristics at treatment initiation
are presented in Table 1. All study groups had a
mean age of about 40 years and were equally
divided in sex. Almost all subjects qualiﬁed for
Medicaid under the Blind and Disabled Programs,
rather than other Medicaid programs, which are
less directly based upon disability. The olanzapine
group had over twice as much prior clozapine use
as either other group. The risperidone group had
signiﬁcantly less prior use of depot antipsychotic
and antimanic medications than either other
group. Most olanzapine initiators were using
another antipsychotic medication on the day they
started olanzapine, whereas most haloperidol initi-
ators were not, with risperidone initiators being
fairly evenly divided. This may indicate a greater
likelihood that olanzapine initiators were switching
to olanzapine from another antipsychotic medica-
tion, rather than having recently been off medica-
tion, since a few weeks overlap in use is
recommended when switching from one antipsy-
chotic medication to another [45,46]. Twenty-nine
percent of the olanzapine initiators had been in an
ACT program in the prior year, compared to 20%
of the risperidone initiators and 17% of the
haloperidol initiators. The most dramatic prior
service use differences were in hospitalizations for
schizophrenia, with haloperidol initiators having
much more prior hospital use than either olanzap-
ine or risperidone and risperidone having signiﬁ-
cantly more than olanzapine. Prior inpatient costs
reﬂected the same pattern. The olanzapine group
also differed from both other groups in the other
component costs, having lower physician costs and
Gibson et al.28
notably higher prior CMHB costs, possibly driven
by ACT, and medication costs.
Patterns of  Use
The mean initial daily doses were 9.9 mg for olan-
zapine, 3.8 mg for risperidone, and 18.2 mg for
haloperidol. Three months after initiation, the mean
daily doses of those still using their index medica-
tion were 14.2, 4.5, and 20.4 mg, respectively. As
indicated in Table 2, after 3 months of treatment,
the percentage of olanzapine initiators who were
using olanzapine as their only antipsychotic medi-
cation had increased from 41% to 46% (P = .18).
The portion of risperidone initiators still using ris-
peridone as their only antipsychotic medication had
dropped from 61% to 42% (P < .0001), and the
portion among haloperidol initiators had dropped
from 81% to 39% (P < .0001).
Relative to olanzapine initiators, a much greater
portion of risperidone and haloperidol initiators
were not taking their index medication at 3 months
(35, 47, and 58%, respectively; P < .005 for each
pairwise comparison), and a much greater portion
were taking no antipsychotic medication at all (20,
32, and 44%, respectively; P < .0001 for each pair-
wise comparison). A similar persistence pattern was
evident in the time to the ﬁrst gap in index medica-
tion therapy. Haloperidol subjects’ ﬁrst gap in index
treatment occurred after an average of 3 months,
the risperidone group’s occurred an average of
about 1 month later, and the olanzapine group’s
was yet another 1 month later (hazard ratios, O vs.
H = 0.51, P < .001; R vs. H = .72, P < .001; O vs.
R = .73, P = .01). Likewise, the haloperidol group
spent an average of about one-third of the postpe-
riod with their index medication, whereas the risp-
eridone and olanzapine groups had their index
medication an average of 49% and 61% of the
time, respectively (P < .0001 for each pairwise
comparison).
Covariate Effects on Total Cost of  Care
The regression models had adjusted r2 values rang-
ing from .16 to .56, generally reﬂecting moderately
good ﬁts. As might be expected, component costs in
the prior period were signiﬁcant predictors of total
and corresponding component costs in the postpe-
riod (Table 3). For instance, a dollar increase in
prior period physician costs was associated with an
increase of $0.85 in postperiod total costs, $0.92 in
postperiod costs excluding medication costs, and
$0.52 in postperiod physician costs. Use of ACT in
the prior period was associated with about $2000
greater postperiod total costs, probably because of
continued use of this intensive service. Prior period
day program services were associated with $450
greater postperiod index medication costs, possibly
because day programs may encourage adherence to
pharmacotherapy.
Medication Effects on Total Cost of  Care
There was no signiﬁcant difference between the
medications in their impact on total cost of care, as
indicated in the ﬁrst row of Table 4. The greatest
numeric difference was between risperidone and
haloperidol, with the $914 difference representing
only 6% of the overall average postperiod total
cost, $14,512. The relatively minor inﬂuence of
medication choice on total cost is apparent in the
ﬁrst three columns of Fig. 1.
Although total costs were similar for the three
medication groups, the component costs differed
substantially. Olanzapine’s costs for all medica-
tions and services other than the index medica-
tion were $1791 lower than for risperidone
(P = .002) and $2080 lower than for haloperidol
(P = .003). The major portion of this difference
was driven by signiﬁcantly lower inpatient costs
for the olanzapine group (–$1336, P = .004 vs.
risperidone; –$1755, P = .002 vs. haloperidol),
with most of the balance being due to lower costs
for other medications (–$444, P < .0001 vs. risp-
eridone; –$363, P = .002 vs. haloperidol). This
more than offset the signiﬁcantly higher medica-
tion cost associated with olanzapine (+$1063,
P < .0001 vs. risperidone; +$2269, P < .0001 vs.
haloperidol). The only statistically signiﬁcant cost
difference between risperidone and haloperidol
Table 2 Patterns of  use (%): antipsychotic (AP) medication persistence and concomitant use of  other AP medications
Medication N
At Initiation After 3 months
Days
to ﬁrst
gap
Postperiod 
days (%) with
therapy
Only
index drug
Index
drug and
another AP
Only
index drug
Index
drug and
another AP
AP
other than
index drug
No AP
medication
Haloperidol 252 81 19 39 3 14 44 91 36
Risperidone 481 61 39 42 11 15 32 128 49
Olanzapine 458 41 59 46 19 15 20 166 61
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was in index medication cost, with risperidone’s
being $1206 greater (P < .0001).
Sensitivity Analyses
The exclusion of high cost outliers resulted in the
elimination of 11 olanzapine, 25 risperidone,
and 19 haloperidol subjects. When these subjects
were added to the regression models, the differences
between olanzapine and the other medications
increased. Olanzapine was associated with $2552
lower total cost than risperidone (P = .009) and
$2323 lower costs than haloperidol (P = .046). The
$229 difference in total costs between risperidone
and haloperidol was not signiﬁcant (P = .86). The
results of the sensitivity analyses are shown in the
last four rows of Table 4.
The second sensitivity analysis limited treatment
initiations to those occurring after October 1996,
when olanzapine was made available. The group
sizes were 446 for olanzapine, 134 for risperidone,
and 75 for haloperidol. Olanzapine total costs were
just slightly ($7) lower than risperidone, and risp-
eridone’s were $572 lower than haloperidol’s. None
of the pairwise total cost differences were stati-
stically signiﬁcant (P > .55 for all three compari-
sons). Despite the much smaller sample size, total
costs excluding the index medication expense were
signiﬁcantly lower for olanzapine than haloperidol
(–$2858, P = .006).
The ﬁnal sensitivity analysis limited the popula-
tion to those subjects who were using no other
antipsychotic medication when they initiated their
index medication. This comprised 189 olanzapine,
294 risperidone, and 204 haloperidol subjects.
Unlike in the main analysis, total costs were $322
greater for olanzapine than risperidone, but the
associated P value was fairly large (P = .72). As in
the main analysis, haloperidol had the lowest total
cost, and total costs excluding the index medication
expense were lowest for olanzapine and highest for
haloperidol. With the reduced sample size, none of
the cost differences were statistically signiﬁcant.
Table 3 Results of  regressions of  index medication and preinitiation characteristics on postinitiation total cost, postinitiation
service cost (excluding medication cost), and postinitiation component costs
Total
Total 
excluding 
index
medication Inpatient Physician CMHB
Non-index
medication
Index 
medication
Index medication (reference: olanzapine)
Risperidone $727.89 $1790.69* $1336.47* $94.10 –$84.29 $444.41‡ –$1062.80‡
Haloperidol –$188.74 $2080.14* $1754.70* $131.62 –$169.38 $363.21† –$2268.89‡
Female $627.73 $796.47 $242.01 $45.71 $422.23 $86.52 –$168.75*
Age (in years) $12.74 –$0.23 $93.83 $21.44 –$99.98 –$15.52 $12.97
Age squared $0.32 $0.43 –$0.59 –$0.16 $0.97 $0.22 –$0.11
Medicaid Blind and Disabled Program $1685.77 $1886.76 $1595.20 $433.48* $297.11 –$439.03* –$200.99
Quarter of  study period $115.60 $137.00 $16.39 –$7.06 $33.31 $94.35‡ –$21.40
Using another antipsychotic on index date $359.80 $280.85 $131.88 –$17.84 $44.73 $122.07 $78.94
Medication use in prior 12 months
Clozapine –$838.81 –$1009.55 –$866.47 –$302.64* –$19.32 $178.88 $170.74
Depot $159.29 $153.24 –$147.84 –$58.52 $305.07 $54.53 $6.05
Other antipsychotic§ $52.90* $55.87* $18.71 $2.38 $30.02† $4.76 –$2.98
Antimanic (lithium or anticonvulsant) –$566.53 –$653.76 –$533.08 –$139.42 –$16.65 $35.40 $87.23
Asthma medications $1231.41 $1401.28 $1042.91 $228.65† –$142.08 $271.81† –$169.87
Cardiovascular medications –$618.78 –$560.01 –$98.67 $6.54 –$531.82 $63.95 –$58.77
Diabetes medications $647.70 $719.32 $571.88 $129.26 $186.74 –$168.55 –$71.63
Service use in prior 12 months
Residential services –$638.62 –$299.47 –$582.50 –$2.80 –$62.15 $347.99 –$339.15
Assertive community treatment $1977.85* $2038.40* $461.85 $15.49 $1331.46‡ $229.61 –$60.55
Day program services $548.85 $99.22 $238.50 $4.57 –$140.89 –$2.97 $449.64†
Case management services $61.54 $8.24 –$834.83 –$107.24 $930.96‡ $19.35 $53.30
Any diagnosis-related inpatient days $1300.59 $1383.57 $907.63 $163.23 $140.15 $172.57 –$82.97
Number of  diagnosis-related inpatient days $69.37 $73.75 $72.84* –$0.84 $3.22 –$1.48 –$4.38
Service cost in prior 12 months (in US dollars)
Inpatient costs $0.19* $0.17* $0.15* $0.00 $0.02 $0.00 $0.02
Physician costs $0.85† $0.92‡ $0.37 $0.52‡ –$0.03 $0.06 –$0.07*
CMHB costs $0.73‡ $0.71‡ –$0.01 –$0.01 $0.75‡ –$0.01 $0.02*
Medication costs $0.85‡ $0.76‡ $0.08 $0.05* –$0.03 $0.67‡ $0.09‡
Intercept $1887.85 –$241.58 –$3069.17 –$614.74 $2979.52* $462.81 $2129.43‡
Adjusted R2 .29 .28 .16 .33 .56 .53 .36
*P < .05.
†P < .01.
‡P < .001.
§Excludes clozapine and depot antipsychotic medications
Note: All P values in Table 3 are based on t tests using the regression coefﬁcient and its standard error.
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Discussion
The impact of olanzapine, risperidone, or haloperi-
dol treatment on postperiod total costs was fairly
small, relative to the average total cost of $14,512
in the year after treatment initiation. The largest dif-
ference, being between haloperidol and risperidone,
was only $917 and represented only 6% of the total
cost. The differences in total cost were not statisti-
cally different between the groups. Given the treat-
ment group sizes and the observed variation in cost,
a difference of at least $1140 would have been nec-
essary to achieve statistical signiﬁcance.
On the other hand, medication treatment had a
signiﬁcant impact on component costs. The most
notable differences in component cost changes
were in inpatient and medication costs. The index
medication cost was much higher for olanzapine
than for either other medication and was much
higher for risperidone than for haloperidol. Never-
theless, for every dollar of excess index medication
cost in the olanzapine group relative to the risperi-
done group, inpatient costs were $1.26 lower and
other medication costs were $0.42 lower. For
every dollar of excess acquisition cost for olanzap-
ine verses haloperidol, inpatient costs were $0.77
lower, and other medication costs were $0.16
lower. For every dollar of excess acquisition cost
for risperidone verses haloperidol, inpatient costs
were $0.35 lower, and other medication costs
were $0.07 lower, although neither of these ﬁnal
two component cost differences was statistically
signiﬁcant.
These results are consistent with those from the
only randomized comparison of olanzapine and ris-
peridone to present component costs [22] and from
one nonrandomized comparison that presented
adjusted component costs [32]. Both studies found
olanzapine to be associated with higher total med-
ication costs and with numerically lower inpatient
[22] or signiﬁcantly lower nonmedication costs
[32]. Like this study, the randomized trial indi-
cated no statistically signiﬁcant effect on total cost,
whereas the nonrandomized comparison, per-
formed within a privately insured population,
found olanzapine to be associated with a lower total
cost. Unlike this study, another study of olanzapine
and risperidone within a Medicaid population
found signiﬁcantly lower total costs associated with
olanzapine [24]. A nonrandomized comparison
within a Veteran’s Health Administration facility
found a very different result, with olanzapine being
associated a greater increase in both medication and
inpatient costs [33].
The differences in medication persistence have
implications for both costs and quality of care. For
instance, annual acquisition costs for olanzapine
would be expected to be 25% greater than those of
risperidone, purely because olanzapine was associ-
ated with 25% more days of treatment (see
Table 2). Part of the lower inpatient cost associated
with olanzapine may also be attributable to the
Table 4 Average postperiod costs by component and medication effects on postperiod costs: primary analysis and sensitivity
analyses
Overall
postperiod
average
Olanzapine
compared to
risperidone
Risperidone
compared to
haloperidol
Haloperidol 
compared to 
olanzapine 
Difference P value Difference P value Difference P value
Total cost $14,512 –$728  .22 $917  .25 –$189  .79
Total cost excluding index medication $13,076 –$1791  .002 –$289  .72 $2080  .003
Component costs
Inpatient costs $4,529* –$1336  .004 –$418  .53 $1755  .002
Physician costs $972 –$94  .16 –$38  .70 $132  .13
CMHB costs $5,646 $84  .75 $85  .77 –$169  .58
Nonindex medication costs $1,929 –$444  <.0001 $81  .40 $363  .002
Index medication cost $1,437 $1063  <.0001 $1206  <.0001 –$2269  <.0001
Sensitivity analyses
Including cost outliers
Total cost $17,167 –$2552  .009 $229  .86 $2323  .046
Total cost excluding index medication $15,752 –$3616  .0002 –$954  .46 $4570  .0001
Initiations after October 1996
Total cost $14,577 –$7  .99 –$572  .71 $579  .58
Total cost excluding index medication $12,690 –$963  .24 –$1895  .22 $2858  .006
No other antipsychotic on index date
Total cost $13,561 $322  .72 $626  .52 –$948  .35
Total cost excluding index medication $12,467 –$783  .37 –$472  .63 $1255  .22
*Within inpatient costs, about 60% were for psychiatric hospitalizations, 20% for other hospitalization, and 20% for long-term care facilities.
Note: All P values in Table 4 are based on randomization tests of  the multivariate models, as described under Methods.
CMHB = Community Mental Health Board.
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increased adherence to treatment. Persistence with
antipsychotic pharmacotherapy is also considered
part of good quality treatment [47]. The greater
persistence of risperidone over haloperidol, and of
olanzapine over both risperidone and haloperidol,
could be interpreted as an indicator of greater
patient beneﬁt. Nevertheless, the differences in per-
sistence need to be interpreted with some caution,
because they are unadjusted statistics. They may
reﬂect initiators’ predispositions to adhere to phar-
macotherapy, rather than differences caused by the
medications. They may also be an effect of the
greater use of ACT programs among persons
treated with olanzapine, because ACT has been
reported to improve medication adherence [48]. To
understand whether the differences in persistence
were attributable to the speciﬁc medication charac-
teristics, or to other factors, a multivariate analysis
of persistence would be needed, especially given the
differences among the groups’ prior medication
use. Nevertheless, that analysis was beyond the
scope of permission granted for use of Michigan’s
data.
The “Medicaid-only” clients presented in this
study are those whose costs are most completely
captured within the Medicaid system. Nevertheless,
the Michigan Medicaid system also has a substan-
tial number of dually enrolled clients, who had both
Medicare and Medicaid coverage. A separate anal-
ysis of Medicaid costs for these dual clients was per-
formed, using variables and methods identical to
those of this study. The details of this analysis of
dually enrolled clients are available from the corre-
sponding author. In brief, group sizes were 801 for
olanzapine, 606 for risperidone, and 288 for
haloperidol. The differences in medication persist-
ence were consistent in direction and statistical sig-
niﬁcance with those of the main analysis; the dually
enrolled haloperidol group spent an average of 37%
of the postperiod with their index medication, com-
pared to 54% for risperidone and 61% for olanza-
pine (P < .0001 for each pairwise comparison), and
the likelihood of stopping differed signiﬁcantly
(hazard ratios, O vs. H = 0.50, P < .001; R vs.
H = 0.59, P < .001; O vs. R = 0.86, P = .01). With
Medicare being ﬁrst payer for most dual client inpa-
tient costs, Medicaid inpatient payments repre-
sented only 9% of Medicaid total costs. Among the
Medicaid-only clients, inpatient cost represented
31% of Medicaid total costs (see column 1 of
Table 4). As might be expected with this discount-
ing of inpatient costs, medication acquisition cost
became a more prominent driver of total cost. Total
costs for olanzapine were $829 higher than those
Figure 1 Expected total and component costs for average patient* in year after initiation of  index medication. *Expected average patient costs
calculated multiplying the regression coefﬁcients by the overall population averages for each regression parameter other than index medication,
summing the results, and then adding the index medication-speciﬁc coefﬁcients. The result is the expected postperiod cost, adjusted for all variables
shown in Table 3, including demographics, prior service use, prior medication use, and prior cost. †Signiﬁcantly different from haloperidol group,
P < .01. ‡Signiﬁcantly different from haloperidol group, P < .001. §Signiﬁcantly different from risperidone group, P < .01. ||Signiﬁcantly different from
risperidone group, P < .001.
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associated with haloperidol (P = .02), with this dif-
ference representing 7% of the average total post-
period costs ($11,207). Risperidone’s $681 greater
total cost than haloperidol was not signiﬁcant
(P = .08), and neither was the $148 difference
between the risperidone and olanzapine groups
(P = .60). As in the nondual client analysis, the post-
period costs excluding index medication were sig-
niﬁcantly lower for olanzapine than risperidone
(–$840, P = .001) or haloperidol (–$1418, P =
.0001). The $578 difference between risperidone
and haloperidol was not statistically signiﬁcant
(P = .13). The primary drivers of these differences
were nonindex medication costs, which were $540
lower for olanzapine than risperidone (P < .0001)
and $692 lower for olanzapine than haloperidol
(P < .0001). The only other signiﬁcant differences in
component costs were the inpatient cost for olanza-
pine ($494 lower than haloperidol, P = .01), and
each pairwise comparison of index medication cost
(olanzapine $447 greater than risperidone and
$1555 greater than haloperidol and risperidone
$1108 greater than haloperidol; P < .001 for each
difference).
Limitations
The baseline statistics in Table 1 indicate some
notable differences among the three treatment
groups. The olanzapine initiators had a more com-
plex medication history than the risperidone initia-
tors, with more prior clozapine use (indicating
treatment refractory clients), more prior depot use
(indicating clients who tend to be less adherent to
their medication regimen), and more prior use of
bipolar disorder medications. The medication his-
tory of haloperidol initiators was somewhat more
complex than the risperidone group, having more
prior depot use, but was less complex than the olan-
zapine group, having less prior clozapine use.
Table 2 indicates that olanzapine initiators were
much more likely to be switching from another
antipsychotic, rather than starting a new course of
therapy after not having been on an antipsychotic
medication for some time. So olanzapine initiators
may have been more treatment refractory and chal-
lenging to treat with pharmacotherapy, relative to
haloperidol initiators and especially relative to ris-
peridone initiators. The analysis included statistical
adjustments for these differences, but, like any sta-
tistical adjustment, the adjustments are likely to be
imperfect [49,50].
Table 1 also shows notable differences in prior
service use between the groups. Schizophrenia-
related hospital use in the prior year was much
higher in the haloperidol group than in the risperi-
done group and was signiﬁcantly lower in the olan-
zapine group than in either other group. On the
other hand, prior use of ACT was signiﬁcantly
higher in the olanzapine group than in either other
group. ACT is an intensive outpatient management
approach that is generally targeted toward people
who are at especially high risk of relapse and hos-
pitalization. The groups clearly differed in prior
service use, but it is difﬁcult to determine which
group’s prior service use indicates a likelihood of
having greater subsequent costs. Although the anal-
ysis included statistical adjustments for these differ-
ences, as well as for differences in prior service
costs, adjustment may have been incomplete.
Another study limitation is the potential that some
hospitalizations were omitted. Medicaid does not
reimburse inpatient stays at large state psychiatric
hospitals, so such services are not represented in the
data. In Michigan in 1997, there were 917 state psy-
chiatric hospital admissions of persons with schiz-
ophrenia, not reimbursed by Medicaid [51]. In the
same year, there were 7010 Medicaid-reimbursed
hospital admissions of persons with schizophrenia
[52]. Based on this, up to 12% (917/7927) of hos-
pitalizations may have been missing from the anal-
ysis in this article. The actual portion missing is
probably somewhat smaller, because many of the
917 state facility admissions may not have been for
Medicaid enrollees, and stays of over 30 days in a
state facility would interrupt the continuous Med-
icaid eligibility that was required for inclusion in
this study. Nevertheless, if the portion of state facil-
ity admissions differed over time among the groups
in this study, the hospitalization results may not
accurately reﬂect subjects’ relative likelihood of
being hospitalized. Therefore, the results of this
study may only be generalizable to hospitalization
cost reimbursed by Medicaid.
These differences in prior medication and service
use probably reﬂect some differences in severity.
When a new drug enters the market, it is likely that
the ﬁrst patients to receive the medication are those
not responding well to previously available drugs.
This study covers treatment episodes that began
between January 1996 and September 30, 1997.
Olanzapine became available midway through this
period, in October 1996. Although the average total
prior period costs for olanzapine initiators were
between those for the haloperidol and risperidone
initiators, there may have been some greater sever-
ity among the olanzapine group. In fact, the medi-
cation history of olanzapine initiators indicated that
they were more treatment refractory. This may have
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created greater opportunity for improvement or
may have made improvement less likely. It is difﬁ-
cult to predict whether or how the study results
might be affected if more information about clinical
differences between groups were available for the
analysis. The administrative claims data used in this
study did not include direct clinical measures
regarding subjects’ history and course of illness;
having such measures might have clariﬁed these
results.
In summary, there were notable baseline differ-
ences in medication history, prior hospital use, and
prior use of ACT, as well as in concomitant anti-
psychotic use at treatment initiation. Although the
analyses included adjustment for these factors,
some confounding may persist and may have inﬂu-
enced the results to either increase or decrease the
differences between groups. The absence of clinical
measures may also have resulted in confounding,
again in an unknown direction. The results are most
relevant to Medicaid covered persons with schizo-
phrenia being treated in outpatient settings. The
results may not pertain to recently institutionalized
patients, or to those initiating two of the study
medications within 1 month, because they were
excluded. Although high cost patients and dually
enrolled clients were also excluded, a sensitivity
analysis indicated that the general results also apply
to them.
Finally, the primary outcome in this study was
cost. Data were not available for assessing person-
centered outcomes such as symptom change, func-
tioning, or quality of life. The outcome most
reﬂective of impact on person’s lives was hospitali-
zation cost, which indicated that persons using
olanzapine may have the least hospital use, whereas
those using haloperidol may have the most. The rel-
ative value of these medications would be more
clearly established were there measures of more
direct relevance to the goal of health care: the well-
being of the client.
Conclusion
In this study, olanzapine was associated with a
reduction in other health-care expenditures, relative
to haloperidol. The reduction associated with risp-
eridone was not statistically signiﬁcant. The analy-
sis indicated that total cost of schizophrenia care
may be similar between olanzapine, risperidone, or
haloperidol, but component costs may differ. Rela-
tive to use of risperidone or haloperidol, use of
olanzapine may increase pharmacy spending, but
may decrease hospitalization and long-term care
facility costs and may be associated with more opti-
mal medication use patterns—less cost for other
medications and possibly greater persistence with
the antipsychotic medication. Use of risperidone
may also increase pharmacy costs and possibly
improve persistence, relative to haloperidol. These
results are consistent with those of other total and
component schizophrenia care cost analyses.
Eli Lilly and Co. funded the work by Millman USA on
this study and the manuscript.
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